Inflammatory Bowel Disease Research Program
The Inflammatory Bowel Disease Research Program at NYU Langone Health bridges basic, clinical, and educational disciplines and brings together faculty who build on the breadth of our immunology, microbiology, and cell biology research to foster cross-disciplinary collaborations and studies. Our mission is to build on our institution’s tradition of turning basic science discoveries into treatments for inflammatory bowel diseases (IBD) including Crohn’s disease and ulcerative colitis.
Following their research on immune signaling molecules, NYU Langone microbiologists worked with pharmaceutical companies to develop the drug infliximab, which blocks one such molecule called TNF-α. It remains among the most commonly used therapies for IBD.
Faculty at the Inflammatory Bowel Disease Research Program work hand-in-hand with gastroenterologists and surgeons at NYU Langone’s clinical Inflammatory Bowel Disease Center with the goal of discovering new treatment strategies and how best to apply them to improve patient care.
Our Leadership
Ken H. Cadwell, PhD, the Recanati Family Professor of Microbiology and professor in the Departments of Microbiology and Medicine is our program director. Dr. Cadwell is recognized for his research on how our immune system is regulated by the diverse microbes we encounter throughout our lives. His discoveries have contributed to our understanding of how imbalances in our relationship with microbes in the gut can lead to inflammation, as seen in patients with IBD.
Dr. Cadwell works together with other members of the leadership team to integrate basic and clinical research with training objectives of the Inflammatory Bowel Disease Research Program. Jordan E. Axelrad, MD, MPH, directs our clinical and translational inflammatory bowel disease research efforts and oversees the gastrointestinal diseases biorepository. Dr. Axelrad is recognized for his research on malignant and infectious complications of IBD, specifically, in elucidating how exposures such as gastrointestinal infections may complicate IBD or trigger it to develop.
David P. Hudesman, MD, and Feza Remzi, MD, are co-directors of our Inflammatory Bowel Disease Center. Together with Dr. Cadwell and Dr. Axelrad, they manage IBD research studies and clinical trials representing partnerships among clinicians, scientists, and industry.
Available Positions
We are hiring research scientists to join our team. Learn more about our available positions.
Select Faculty Publications
Real-World Surgical and Endoscopic Recurrence Based on Risk Profiles and Prophylaxis Utilization in Postoperative Crohn's Disease
Clinical gastroenterology & hepatology. 2024 Apr ; 22:847-857.e12
Histologic Activity in Inflammatory Bowel Disease and Risk of Serious Infections: A Nationwide Study
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2024 Apr ; 22:831-846
Role of Antigenic Stimulation in Cutaneous T-Cell Lymphomas
Journal of investigative dermatology. 2024 Apr ; 144:755-763
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer
Science advances. 2024 Mar 29; 10:eadm9859
Outcomes after Fecal Microbiota Transplantation in combination with Bezlotoxumab for Inflammatory Bowel Disease and Recurrent C . difficile Infection
The American journal of gastroenterology. 2024 Mar 19;
Improving Sleep Using Mentored Behavioral and Environmental Restructuring (SLUMBER)
Journal of the American Medical Directors Association. 2024 Mar 14;
Implementation Outcomes for the SLUMBER Sleep Improvement Program in Long-Term Care
Journal of the American Medical Directors Association. 2024 Mar 14;
The thymocyte-specific RNA-binding protein Arpp21 provides TCR repertoire diversity by binding to the 3'-UTR and promoting Rag1 mRNA expression
Nature communications. 2024 Mar 11; 15:2194